The effects of SGLT2 inhibitors on HF hospitalisation appeared to be remarkably consistent across the class (approximately a 30% reduction in hospitalisation for HF; see Table S1 in the Electronic Supplementary Material). The gene discussed is SLC5A2; the disease is hydrops fetalis.